Popular
COYA · Medicine & biotech · U.S.

Coya Therapeutics

Develops drugs to treat ALS and other brain diseases.

Company Health

61
/100
Mixed
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $267 of every $100 in sales.
Is it growing?
21 of 25 · Good
Sales grew about 15% a year over the last 2 years.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.

Who owns it

1 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Coya Therapeutics’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales went from $0 in 2022 to $7.95 million in 2025, and it lost money every year.
2025
Sales
$7.95 million
Loss
$21.2 million

What it owns and what it owes

At the end of 2025 it owned $50.0 million, including $46.8 million in cash, and owed $6.92 million.

Key facts

From its yearly report for 2025.
Sales
$7.95 million
Loss
$21.2 million
Cash in the bank
$46.8 million
Everything it owes
$6.92 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Mar 16, 2026
Figures from Coya Therapeutics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy